Zhang Hong, Wang Dong-xin, Xiao Feng, Li Jian, He Zhi-song, Wan Yuan-lian
Department of Anaesthesia and Critical Care Medicine, Peking University First Hospital, Beijing, China.
Interact Cardiovasc Thorac Surg. 2009 Nov;9(5):788-92. doi: 10.1510/icvts.2009.208512. Epub 2009 Aug 3.
The aim of this study was to analyze the results of major non-cardiac surgery in patients with severe coronary arterial disease who underwent concomitant vs. previous myocardial revascularization (MR) in terms of operative complications and hospital stay. Between June 1999 and October 2008, 37 patients with coronary arterial disease underwent neoplastic resection at our hospital. Fourteen patients with a curable left-main or multiple-vessel disease received surgical MR concomitantly, while 23 patients previously underwent surgical or transluminal MR. Univariate analysis determined the impact of the timing of MR on operative complications and hospital stay. The overall mortality and morbidity rates were 3% and 65%, respectively. Compared with simultaneous MR, neoplastic surgery with previous MR had shorter postoperative hospital stay. Occurrence of postoperative complications was influenced by surgical duration (P=0.014). Postoperative length of hospital stay was affected by the timing of revascularization (P=0.008) and surgical duration (P=0.007). Previous MR can shorten postoperative hospital length of stay for current major non-cardiac surgeries in patients with severe coronary artery disease (CAD). For patients with concomitant severe CAD and clinically rapidly progressive malignant neoplasm, simultaneous neoplastic resection and MR is associated with acceptable operative mortality.
本研究旨在分析重度冠状动脉疾病患者在接受同期与既往心肌血运重建(MR)的情况下进行非心脏大手术的手术并发症和住院时间结果。1999年6月至2008年10月期间,37例冠状动脉疾病患者在我院接受了肿瘤切除手术。14例患有可治愈的左主干或多支血管疾病的患者同时接受了外科MR,而23例患者此前接受过外科或经皮腔内MR。单因素分析确定了MR时机对手术并发症和住院时间的影响。总体死亡率和发病率分别为3%和65%。与同期MR相比,既往接受过MR的肿瘤手术术后住院时间较短。手术持续时间影响术后并发症的发生(P=0.014)。术后住院时间受血运重建时机(P=0.008)和手术持续时间(P=0.007)的影响。既往MR可缩短重度冠状动脉疾病(CAD)患者当前非心脏大手术的术后住院时间。对于合并严重CAD和临床快速进展性恶性肿瘤的患者,同期肿瘤切除和MR的手术死亡率可接受。